Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

AIDS

Volumn 28, Issue 3, 2014, Pages 325-334

  Puertas, Maria C ^a   Massanella, Marta ^a   Llibre, Josep M ^b   Ballestero, Monica ^a   Buzon, Maria J ^a   Ouchi, Dan ^a   Esteve, Anna ^c   Boix, Jaume ^b   Manzardo, Christian ^d   Miró, Josep M ^d   Gatell, Josep M ^d   Clotet, Bonaventura ^a,b   Blanco, Julià ^a   Martinez Picado, Javier ^a,e  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Center for Epidemiological Studies on HIV/AIDS of Catalonia (CEEISCAT)   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Early infection; HIV 1; Maraviroc; Raltegravir; Treatment intensification; Viral reservoir

Indexed keywords

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

EID: 84894046809     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000066     Document Type: Article

References (40)

1. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
3. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155.
4. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012; 26: 1261-1268.
5. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16:1149- 1167.
6. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cellto- cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95-98.
7. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
8. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4Rcell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012; 109:9523-9528.
9. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
10. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.
11. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012; 17:355- 364.
12. Massanella M, Esteve A, Buzon MJ, Llibre JM, Puertas MC, Gatell JM, et al. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013; 63:152-160.
13. Pierson T, Hoffman TL, Blankson J, Finzi D, Chadwick K, Margolick JB, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 2000; 74:7824-7833.
14. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732.
15. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803-813.
16. Brussel A, Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 2003; 77:10119- 10124.
17. WuH, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999; 55:410-418.
18. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Gueye NF, Gueye PM, et al. Modeling CD4R cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal. Am J Trop Med Hyg 2009; 80:1047- 1053.
19. Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzon MJ, Martinez- Picado J, et al. Modelling HIV-1 2-LTR dynamics following raltegravir intensification. J R Soc Interface 2013; 10: 20130186.
20. Wu H, Ding AA, De Gruttola V. Estimation of HIV dynamic parameters. Stat Med 1998; 17:2463-2485.
21. Thiebaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2004; 74:255-260.
22. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
23. Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell SB, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998; 161:3195-3201.
24. Reynes J, Baillat V, Portales P, Clot J, Corbeau P. Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy. JAMA 2004; 291:46.
25. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23.
26. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762-1764.
27. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452-1465.
28. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8R and CD4R T lymphocytes. Proc Natl Acad Sci U S A 2000; 97:3382-3387.
29. Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother 2012; 56:4154-4160.
30. Garrigue I, Pellegrin I, Hoen B, Dumon B, Harzic M, Schrive MH, et al. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS 2000; 14:2851-2855.
31. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948.
32. Morand-Joubert L, Marcellin F, Launay O, Guiramand-Hugon S, Gerard L, Yeni P, et al. Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081). J Acquir Immune Defic Syndr 2005; 38:268-276.
33. Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011; 25:2069-2078.
34. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005; 79:5203-5210.
35. Chavez HH, Tran TA, Dembele B, Nasreddine N, Lambotte O, Gubler B, et al. Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo. J Acquir Immune Defic Syndr 2007; 45:247-249.
36. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4R cell rises in HIV-infected patients. PLoS One 2010; 5:e13188.
37. Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S, Imami N. CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection. Mol Med 2012; 18:1240-1248.
38. Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4R T-cell recovery: a randomized trial. Blood 2013; 121:4635-4646.
39. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553- 1561.
40. Markowitz M, Evering T, Caskey M, Figueroa A, Rodriguez K, La Mar M, et al. A randomized open-label trial of 5-drug vs 3-drug standard PI-based cART initiated during acute and early HIV-1 infection: 48-week results. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011.